Research Summary: The following information is provided for research context only.
Semaglutide Research Overview
Semaglutide is a GLP-1 receptor agonist analogue with an extended half-life relative to native GLP-1, achieved through fatty acid modification that enables albumin binding and resistance to DPP-4 enzymatic degradation. It has been one of the most widely studied compounds in metabolic and cardiovascular research over the past decade.
Mechanism of Action
Semaglutide binds to GLP-1 receptors expressed in pancreatic beta cells, the hypothalamus, and the gastrointestinal tract. Activation of these receptors stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite via central hypothalamic pathways. Its prolonged half-life makes it a useful reference compound for studying sustained GLP-1 receptor engagement in preclinical models.
Research Applications
Semaglutide has been investigated in preclinical models of: type 2 diabetes and insulin resistance; obesity and energy balance; non-alcoholic steatohepatitis (NASH); cardiovascular risk and inflammation; and neurodegenerative conditions involving GLP-1 receptor pathways. It is commonly used as a reference compound in comparative incretin research alongside Tirzepatide and Retatrutide.
Compound Specifications
Lyophilized Semaglutide 10mg at 99%+ HPLC-UV purity. LCMS-confirmed identity. Molecular weight: 4113.6 Da. Batch SEM010-001. COA included with every order.
Storage and Handling
Store at -20°C prior to reconstitution. Reconstitute with sterile bacteriostatic water. Once in solution, store at 4°C and use within 28 days.
For research use only. Not for human or veterinary use.
Reviews
There are no reviews yet.